Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Kojima, 2020, Randomized phase III keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer, J Clin Oncol, 38, 4138, 10.1200/JCO.20.01888 Kato, 2019, Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 20, 1506, 10.1016/S1470-2045(19)30626-6 Huang, 2020, Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study, Lancet Oncol, 21, 832, 10.1016/S1470-2045(20)30110-8 Daud, 2016, Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma, J Clin Oncol, 34, 4102, 10.1200/JCO.2016.67.2477 Kulangara, 2019, Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer, Arch Pathol Lab Med, 143, 330, 10.5858/arpa.2018-0043-OA Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study, Lancet, 394, 1915, 10.1016/S0140-6736(19)32591-7 Kitagawa, 2019, Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2, Esophagus, 16, 25, 10.1007/s10388-018-0642-8 2019, Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version), Chin J Cancer Res, 31, 223, 10.21147/j.issn.1000-9604.2019.02.01 Sun, 2021, Pembrolizumab plus chemotherapy versus chemotherapy for first-line, advanced esophageal cancer: the randomized, placebo-controlled phase 3 KEYNOTE-590 study, Lancet, 398, 759, 10.1016/S0140-6736(21)01234-4 Chau, 2021, Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study, J Clin Oncol, 39, LBA4001, 10.1200/JCO.2021.39.15_suppl.LBA4001 Abnet, 2018, Epidemiology of esophageal squamous cell carcinoma, Gastroenterology, 154, 360, 10.1053/j.gastro.2017.08.023 Tran, 2005, Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China, Int J Cancer, 113, 456, 10.1002/ijc.20616 Zhang, 2012, Epidemiologic differences in esophageal cancer between Asian and Western populations, Chin J Cancer, 31, 281, 10.5732/cjc.011.10390 Lu, 1991, Relevance of N-nitrosamines to oesophageal cancer in China, IARC Sci Publ, 11 Deng, 2017, Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations, Nat Commun, 8, 1533, 10.1038/s41467-017-01730-x Chen, 2017, Racial differences in esophageal squamous cell carcinoma: incidence and molecular features, Biomed Res Int, 1204082